Findings of cross-sectional and longitudinal studies of plasma Aβ, including autosomal dominant AD cases, sporadic AD cases, Down syndrome cases and population studies, are also discussed.
As expected, the frequency of rescreening improves AD-FY and AD cases avoided.
5 Interestingly, early onset AD accounts only for 5% of total AD cases.
At present, patients included in the study remain clinically diagnosed as probable AD cases and no subjects are neuropathologically confirmed as definite AD cases.
There were 106 autopsy-proven AD cases and 101 controls of similar ages in each test for a total of 212 AD cases and 202 controls.
The major sporadic AD cases exhibit onset in their 70s or even later, whereas the minor, mutation linked, familial AD cases exhibit onset typically during their 50s.
In the present study, AD cases showed significantly elevated mRNA levels of PGRN, when compared with the levels in non-AD cases.
Even a small increase in risk can translate to a large number of AD cases.
We aimed to compare clinical and neuropathological features between typical and atypical AD cases.
During the follow-up, 77 incident AD cases were diagnosed.
Comparison with AD cases shows a decrease in CSF T-Tf (WB) by 39% in CJD+ relative to AD cases (z = 4.92, p<.001) (Figure 1 D).
